Artiva Biotherapeutics Cuts 94% of Staff After Drug Trial Failure

Artiva Biotherapeutics Cuts 94% of Staff After Drug Trial Failure

by

San Diego-based biotech firm Artiva Biotherapeutics is laying off approximately 94 percent of its workforce and abandoning its primary experimental drug after clinical trial results fell short and the company faced scrutiny regarding two patient deaths.

From $300 Million in Capital to Mass Layoffs in Five Months

The swift reversal of fortune hits the company just five months after it raised roughly $300 million from investors. In June, Artiva employed 115 full-time workers and was actively expanding at its headquarters on Morehouse Drive in San Diego. Now, nearly all of those positions are being eliminated.

The core casualty of the shutdown is AlloNK, an off-the-shelf natural killer cell therapy designed to harness the body’s immune system against autoimmune disorders like rheumatoid arthritis. While initial clinical trials showed the treatment was effective, longer-term data revealed that the clinical response did not last long enough to warrant moving into a planned Phase 3 trial. Company executives decided to scrap the program entirely rather than risk a costly late-stage failure.

Patient Safety Scrutiny and Financial Realities

Alongside the trial’s durability issues, Artiva faced scrutiny following the deaths of two clinical trial participants. An independent safety review board and trial investigators assessed both incidents. In the first case, a Phase 2a participant developed a fatal neurological condition known as leukoencephalopathy, which investigators determined was likely linked to fludarabine, a mild chemotherapy regimen commonly administered during immunotherapy trials. A second participant died suddenly about two months after starting treatment, though investigators ruled that death unrelated to AlloNK or any other part of the study regimen, leaving the exact cause undetermined.

Despite holding approximately $319.1 million in cash and investments as of September 30, according to federal filings, the company’s expenses were heavily concentrated in staffing and drug development. Last year, out of roughly $25 million in total spending, $11.8 million went toward drug research and $10.8 million funded personnel.

“Throughout the development of AlloNK, the safety and well-being of patients have remained our highest priority. We are deeply saddened by the deaths of two patients who participated in our clinical studies and extend our sincere condolences to their families,” said Dr. Fred Aslan, chief executive officer of Artiva.

With AlloNK representing its sole developmental program, leadership is now exploring strategic options, including a sale, merger, or total liquidation. Meanwhile, the company faces substantial wind-down expenses, encompassing severance payouts, trial terminations, lease obligations at its San Diego facility, and partner agreements. Following the announcement, Artiva shares dropped roughly 31 percent to about $4.23.

FDA staff cuts hit biotech: Impact of layoffs on drug development

Keep reading

Read next